Aliases:This biomarker is also known as:
- T-cell specific protein p288,
- eosinophil chemotactic cytokine,
- chemokine (C-C motif) ligand 5,
- small inducible cytokine subfamily A (Cys-Cys), member 5,
- T cell-specific protein P228,
- C-C motif chemokine 5,
- small inducible cytokine A5 (RANTES),
- small-inducible cytokine A5,
- t cell-specific protein P228,
- T-cell-specific protein RANTES,
- beta-chemokine RANTES,
- Eosinophil chemotactic cytokine,
- regulated upon activation, normally T-expressed, and presumably secreted,
- Small-inducible cytokine A5,
CCL5 (RANTES) is a chemokine, a subfamily of cytokines. Chemokines form a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. CCL5 is a chemoattractant for blood monocytes, memory T-helper cells and eosinophils and causes the release of histamine from basophils and activates eosinophils. There are several transcript variants that encode different isoforms.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
The chemokine CCL5 (RANTES), a major monocyte chemoattractant expressed by breast tumor cells, has been implicated in the progression of breast cancer.
CCL5 (RANTES) was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity.